Cargando…
H172Y mutation perturbs the S1 pocket and nirmatrelvir binding of SARS-CoV-2 main protease through a nonnative hydrogen bond
Nirmatrelvir is an orally available inhibitor of SARS-CoV-2 main protease (Mpro) and the main ingredient of PAXLOVID, a drug approved by FDA for high-risk COVID-19 patients. Although the prevalent Mpro mutants in the SARS-CoV-2 Variants of Concern (e.g., Omicron) are still susceptible to nirmatrelvi...
Autores principales: | de Oliveira, Vinicius Martins, Ibrahim, Mohamed Fourad, Sun, Xinyuanyuan, Hilgenfeld, Rolf, Shen, Jana |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Journal Experts
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9387537/ https://www.ncbi.nlm.nih.gov/pubmed/35982654 http://dx.doi.org/10.21203/rs.3.rs-1915291/v1 |
Ejemplares similares
-
An Integrative Approach to Dissect the Drug Resistance Mechanism of the H172Y Mutation of SARS-CoV-2 Main Protease
por: Clayton, Joseph, et al.
Publicado: (2023) -
From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease †
por: Göhl, Matthias, et al.
Publicado: (2022) -
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
por: Zhang, Linlin, et al.
Publicado: (2020) -
A Warhead
Substitution Study on the Coronavirus Main
Protease Inhibitor Nirmatrelvir
por: Vankadara, Subramanyam, et al.
Publicado: (2022) -
Multicomponent Synthesis
of the SARS-CoV-2
Main Protease Inhibitor Nirmatrelvir
por: Preschel, H. Daniel, et al.
Publicado: (2023)